Anatara Lifesciences (ASX: ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a specialist life sciences company with expertise in developing products for animal and human health. We are currently focused on building a pipeline of evidence-based, over-the-counter gastrointestinal health products, through in-house development and in-licencing and distribution opportunities. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. Human Applications Our initial Gastrointestinal ReProgramming (GaRP) over-the-counter medicine is focused on addressing the chronic symptoms associated with irritable bowel syndrome (IBS) and the inflammatory bowel diseases (IBD). 11% of the global population is affected by IBS and there are 5 million IBD sufferers worldwide. GaRP has been designed as an everyday option for patients to manage ongoing chronic symptoms as well as minimise episodic flare ups. Animal Applications Anatara’s foundations are built on strong and successful science. Anatara's first product, Detach®, is a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour in livestock) in piglets. Scour in piglets is an expensive, debilitating and in some cases, life-threatening condition. Detach® is safe and effective. It is the result of more than 20 years of scientific research and development. Anatara is evaluating commercialisation opportunities for Detach® including options for launch in Australia, regulatory approval of this product in overseas markets, development of this product for species other than piglets and global or regional licensing of Detach®. About Us Backed by a well credentialed Board and Management team, and world-leading scientific collaborators, Anatara is uniquely positioned to fulfill a significant unmet medical need in gut health.